XOStem

Irvine, United States Founded: 2018 • Age: 8 yrs
Stem cells and bio-artificial organs are developed for diabetes treatment.
Annual revenue - Latest available
Total funding $1.3M 4 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 6 Brand Intelligence

About XOStem

XOStem is a company based in Irvine (United States) founded in 2018 by John Sanderson. XOStem has raised $1.3 million across 4 funding rounds. XOStem operates in a competitive market with competitors including Sernova, Beta Bionics, Inreda Diabetic, Defymed and Captix, among others.

  • Headquarter Irvine, United States
  • Founders John Sanderson
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $1.3 M (USD)

    in 4 rounds

  • Latest Funding Round
    $378 K (USD), Seed

    Feb 16, 2024

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of XOStem

Headcount 1-10
Employee Profiles 8
Board Members and Advisors 1
Employee Profiles
People
Adrian Abalovich
Principal Investigator
People
Lijuan Fu
Senior Scientist
People
Amanda Berner
Laboratory Technician
People
Brad Eckenweiler
CEO

Unlock access to complete

Board Members and Advisors
people
M. Reza Mohammadi
Scientific Advisor

Unlock access to complete

Funding Insights of XOStem

XOStem has successfully raised a total of $1.3M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $378 thousand completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by XOStem

Investments
Premium access

Investment portfolio details for XOStem

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - XOStem

Premium access

Detailed financials for XOStem

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Xostem Comparisons

XOStem Primary company
Description
Stem cells and bio-artificial organs are developed for diabe...
Location
Irvine, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for XOStem

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of XOStem

XOStem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sernova, Beta Bionics, Inreda Diabetic, Defymed and Captix, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Regenerative medicine to deliver proteins and hormones for disease treatment
Locked Locked Locked
Bionic pancreas system for type 1 diabetes is provided.
Locked Locked Locked
Bi-hormonal artificial pancreas is developed for autonomous glucose regulation.
Locked Locked Locked
Develops innovative bio-artificial pancreas technologies for type 1 diabetes treatment.
Locked Locked Locked
Develops innovative bioartificial pancreas technologies for diabetes treatment.
Premium access

Detailed competitors of XOStem

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Xostem

Premium access

Complete news archive for XOStem

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about XOStem

XOStem was founded in 2018 and raised its 1st funding round 2 years after it was founded.

XOStem is headquartered in Irvine, United States. It is registered at Irvine, California, United States.

John Sanderson is the current CEO of XOStem. They have also founded this company.

XOStem is a funded company, having raised a total of $1.3M across 4 funding rounds to date.

XOStem was founded in 2018 in Irvine, United States, within the biotechnology sector. Stem cell technologies and bio-artificial organs are developed for diabetes treatment, with a focus on Type-1 patients through devices that encase and protect insulin-producing cells. Equipment for cell culturing, isolation, and delivery is provided to enable exosome-based product production. Operations center on advancing regenerative therapies for metabolic disorders.

XOStem's top competitors include Sernova, Beta Bionics and Inreda Diabetic.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available